Antimicrobial activities of fidaxomicin

Clinical Infectious Diseases

Volumn 55, Issue SUPPL.2, 2012, Pages

  Goldstein, Ellie J C ^a,b   Babakhani, Farah ^c   Citron, Diane M ^a  

^a RM Alden Research Laboratory ^*  (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c Optimer Pharmaceuticals Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CALCIUM; DRUG METABOLITE; FIDAXOMICIN; MAGNESIUM; OP 1118; UNCLASSIFIED DRUG;

ANTIMICROBIAL ACTIVITY; BACTERIAL STRAIN; BACTERIUM ISOLATE; CLOSTRIDIUM DIFFICILE; CLOSTRIDIUM DIFFICILE INFECTION; COLONY FORMING UNIT; CONTROLLED STUDY; DRUG TREATMENT FAILURE; IN VITRO STUDY; INOCULATION; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PRIORITY JOURNAL; REVIEW;

AMINOGLYCOSIDES; ANTI-BACTERIAL AGENTS; CLINICAL TRIALS AS TOPIC; CLOSTRIDIUM DIFFICILE; CLOSTRIDIUM INFECTIONS; DRUG EVALUATION, PRECLINICAL; DRUG RESISTANCE, BACTERIAL; FECES; HUMANS; HYDROGEN-ION CONCENTRATION; MICROBIAL SENSITIVITY TESTS; RECURRENCE; VANCOMYCIN;

EID: 84863695602     PISSN: 10584838     EISSN: 15376591     Source Type: Journal    
DOI: 10.1093/cid/cis339     Document Type: Review

References (18)

1. Swanson RN, Hardy DJ, Shipkowitz NL, et al. In vitro and in vivo evaluation of tiacumicins B and C against Clostridium difficile. Antimicrob Agents Chemother 1991; 35:1108-11.
2. Theriault RJ, Karwowski JP, Jackson M, et al. Tiacumicins, a novel complex of 18-membered macrolide antibiotics. I. Taxonomy, fermentation and antibacterial activity. J Antibiot 1987; 40:567-74. (Pubitemid 17072152)
3. Babakhani FK, Robert N, Shangle S, et al. Antimicrobial activity and post-antibiotic effect of OPT-89, a new macrocyclic compound, against Clostridium difficile [abstract]. Presented at: 44th Interscience Conference on Antimicrobial Agents and Chemotherapy, 30 October-2 November 2004, Washington, DC.
4. Ackermann G, Löffler B, Adler D, Rodloff AC. In vitro activity of OPT-80 against Clostridium difficile. Antimicrob Agents Chemother 2004; 48:2280-2. (Pubitemid 38691631)
5. Finegold SM, Molitoris D, Vaisanen ML, Song Y, Liu C, Bolaños M. In vitro activities of OPT-80 and comparator drugs against anaerobic bacteria. Antimicrob Agents Chemother 2004; 48:4898-902. (Pubitemid 39577704)
6. Hecht DW, Galang MA, Sambol SP, Osmolski JR, Johnson S, Gerding DN. In vitro activities of 15 antimicrobial agents against 110 toxigenic Clostridium difficile clinical isolates collected from 1983 to 2004. Antimicrob Agents Chemother 2007; 51:2716-9. (Pubitemid 47206204)
7. Credito KL, Applebaum PC. Activity of OPT-80, a novel macrocycle, compared with those of eight other agents against selected anaerobic species. Antimicrob Agents Chemother 2004; 48:4430-4. (Pubitemid 39434908)
8. Karlowsky JA, Laing NM, Zhanel GG. In vitro activity of OPT-80 tested against clinical isolates of toxin-producing Clostridium difficile. Antimicrob Agents Chemother 2008; 52:4163-5.
9. Citron DM, Babakhani F, Goldstein EJ, et al. Typing and susceptibility of bacterial isolates from the fidaxomicin (OPT-80) phase II study for C. difficile infection. Anaerobe 2009; 15:234-6.
10. Goldstein EJ, Citron DM, Sears P, Babakhani F, Sambol SP, Gerding DN. Comparative susceptibilities of fidaxomicin (OPT-80) of isolates collected at baseline, recurrence, and failure from patients in two fidaxomicin phase III trials of C. difficile infection. Antimicrob Agents Chemother 2011; 55:5194-9.
11. Clinical and Laboratory Standards Institute. Methods for antimicrobial susceptibility testing of anaerobic bacteria. 7th ed. CLSI document M11-A7. Wayne, PA: CLSI, 2007.
12. Babakhani F, Seddon J, Robert N, Shue YK, Sears P. Effects of inoculum, pH, and cations on the in vitro activity of fidaxomicin (OPT-80, PAR-101) against Clostridium difficile. Antimicrob Agents Chemother 2010; 54:2674-6.
13. Louie TJ, Emery J, Krulicki W, Bryne B, Mah M. OPT-80 eliminates Clostridium difficile and is sparing of Bacteroides species during treatment of C. difficile infection. Antimicrob Agents Chemother 2009; 53:261-3.
14. Babakhani FK, Seddon J, Robert N, et al. Narrow spectrum activity and low fecal binding of OPT-80 and its major hydrolysis metabolite (OP-1118) [abstract E-2076]. Presented at: 47th Interscience Conference on Antimicrobial Agents and Chemotherapy, 17-20 September 2007, Chicago, Illinois.
15. Babakhani F, Gomez A, Robert N, Sears P. Killing kinetics of fidaxomicin and its major metabolite, OP-1118, against Clostridium difficile. J Med Microbiol 2011; 60:1213-7.
16. Louie T, Miller M, Donskey C, Mullane K, Goldstein EJ. Clinical outcomes, safety, and pharmacokinetics of OPT-80 in a phase 2 trial with patients with Clostridium difficile infection. Antimicrob Agents Chemother 2009; 53:223-8.
17. Gultieri M, Tupin A, Brodolin K, Leonetti JP. Frequency and characterization of spontaneous lipiarmycin-resistant Enterococcus faecalis mutants selected in vitro. Int J Antimicrobial Agents 2009; 34: 605-16.
18. Kurabachew M, Lu S, Krastel P, et al. Lipiarmycin targets RNA polymerase and has good activity against multidrug-resistant strains of Mycobacterium tuberculosis. J Antimicrob Chemother 2008; 62: 713-9.